Involvement of calpain activation in neurodegenerative processes

CNS Drug Reviews

Volumn 12, Issue 2, 2006, Pages 135-148

  Camins, Antoni ^a   Verdaguer, Ester ^b   Folch, Jaume ^c   Pallàs, Mercè ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Amyloid; Calpain; Caspase; Excitotoxicity; Glutamate; Mitochondria; Neurodegenerative diseases

Indexed keywords

3 (4 IODOPHENYL) 2 MERCAPTO 2 PROPENOIC ACID; 3 NITROPROPIONIC ACID; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER; ACRYLIC ACID DERIVATIVE; AK 275; AK 295; ALOXISTATIN; AMYLOID BETA PROTEIN; CALPAIN; CALPASTATIN; CALPEPTIN; CASPASE; CYCLIN DEPENDENT KINASE 5; CYSTEINE PROTEINASE; CYTOSKELETON PROTEIN; GLUTAMIC ACID; MORPHOLINE DERIVATIVE; N (4 FLUOROPHENYLSULFONYL)VALYLLEUCINE; NEUROTOXIN; PD 150606; PD 151746; PEPTIDE DERIVATIVE; SJA 6017; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG PENETRATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXCITOTOXICITY; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; STRUCTURE ANALYSIS;

ANIMALS; CALPAIN; CELL DEATH; ENZYME ACTIVATION; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES;

EID: 33748087835     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2006.00135.x     Document Type: Review

References (85)

1. Alavez S, Moran J, Franco-Cea A, Ortega-Gomez A, Casaletti L, Cameron LC. Myosin Va is proteolysed in rat cerebellar granule neurons after excitotoxic injury. Neurosci Lett 2004;367(9):404-409.
2. Alvarez A, Toro R, Caceres A, Maccioni RB. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 1999;459:421-426.
3. Araujo IM, Verdasca MJ, Leal EC, et al. Early calpain-mediated proteolysis following AMPA receptor activation compromises neuronal survival in cultured hippocampal neurons. J Neurochem 2004;91:1322-1331.
4. Banay-Schwartz M, DeGuzman T, Palkovits M, Lajtha A. Calpain activity in adult and aged human brain regions. Neurochem Res 1994;19:563-567.
5. 2+ exchanger in excitotoxicity. Cell 2005;120:275-285.
6. Bartus RT, Hayward NJ, Elliott PJ, et al. Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra-arterial administration. Stroke 1994;25:2265-2270.
7. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O. Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci 2003;20:357-362.
8. Benuck M, Banay-Schwartz M, DeGuzman T, Lajtha A. Changes in brain protease activity in aging. J Neurochem 1996;67:2019-2029.
9. Biswas S, Harris F, Dennison S, Singh J, Phoenix DA. Calpains: Targets of cataract prevention? Trends Mol Med 2004;10:78-84.
10. Bizat N, Galas MC, Jacquard C, et al. Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology 2005;49:695-702.
11. Bizat N, Hermel JM, Boyer F, et al. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: Implications for Huntington's disease. J Neurosci 2003;23:5020-5030.
12. Bernath E, Kupina N, Liu MC, Hayes RL, Meegan C, Wang KK. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging 2006;27:624-632
13. Brion JP, Couck AM. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5. Am J Pathol 1995;147:1465-1476.
14. Buki A, Farkas O, Doczi T, Povlishock JT. Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury. J Neurotrauma 2003;20:261-268.
15. Carragher NO. Calpain inhibition: A therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006;12:615-638.
16. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. Bid is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/reperfusion. J Biol Chem 2001;276:30724-30728.
17. Chen MJ, Yap YW, Choy MS, et al. Early induction of calpains in rotenone-mediated neuronal apoptosis. Neurosci Lett 2006;397:69-73.
18. Choi WS, Lee EH, Chung CW, et al. Cleavage of Bax is mediated by caspase-dependent or -independent calpain activation in dopaminergic neuronal cells: Protective role of Bcl-2. J Neurochem 2001;77: 1531-1541.
19. Crocker SJ, Smith PD, Jackson-Lewis V, et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 2003;23:4081-4091.
20. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 2004;10: 452-458.
21. Das A, Sribnick EA, Wingrave JM, et al. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: Calpain inhibition provides functional neuroprotection. J Neurosci Res 2005;81:551-562.
22. Donkor IO, Sanders ML. Synthesis of a reported calpain inhibitor isolated from Streptomyces griseus. Bioorg Med Chem Lett 2001;11:2647-2649.
23. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Nakamura M, Shearer TR. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: Amelioration of cataract in cultured rat lenses. Biochim Biophys Acta 1997;1361:304-312.
24. Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci 2002;22:4842-4849.
25. Giese KP, Ris L, Plattner F. Is there a role of the cyclin-dependent kinase 5 activator p25 in Alzheimer's disease? Neuroreport 2005;16:1725-1730.
26. +: Mechanism for its toxicity in cerebellar granule cells. Mol Neurobiol 2004;30:253-64.
27. Gray BC, Skipp P, O'connor VM, Perry VH. Increased expression of glial fibrillary acidic protein fragments and μ-calpain activation within the hippocampus of prion-infected mice. Biochem Soc Trans 2006;34:51-54.
28. Hung KS, Hwang SL, Liang CL, et al. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J Neuropathol Exp Neurol 2005;64:15-26.
29. Kesavapany S, Li BS, Amin N, Zheng YL, Grant P, Pant HC. Neuronal cyclin-dependent kinase 5: Role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide. Biochim Biophys Acta 2004;1697:143-153.
30. Kieran D, Greensmith L. Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration. Neuroscience 2004;125:427-39.
31. Kupina NC, Detloff MR, Bobrowski WF, Snyder BJ, Hall ED. Cytoskeletal protein degradation and neurodegeneration evolves differently in males and females following experimental head injury. Exp Neurol 2003; 180:55-73.
32. Lee KS, Seo SH, Lee YH, et al. Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors. Bioorg Med Chem Lett 2005;15:2857-2860.
33. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;18:405:360-364.
34. Leist M, Volbracht C, Fava E, Nicotera P. 1-Methyl-4-phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol Pharmacol 1998;54:789-801.
35. Li J, Nixon R, Messer A, Berman S, Bursztajn S. Altered gene expression for calpain/calpastatin system in motor neuron degeneration (Mnd) mutant mouse brain and spinal cord. Brain Res Mol Brain Res 1998;53: 174-186.
36. Liou AK, Zhou Z, Pei W, Lim TM, Yin XM, Chen J. BimEL up-regulation potentiates AIF translocation and cell death in response to MPTP. FASEB J 2005;19:1350-1352.
37. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431-568.
38. Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX. Truncation and activation of calcineurin A by calpain 1 in Alzheimer disease brain. J Biol Chem 2005;280:37755-37762.
39. Liu T, Perry G, Chan HW, Verdile G, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004;88:554-563.
40. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001;32:367-381.
41. McCollum AT, Nasr P, Estus S. Calpain activates caspase-3 during UV-induced neuronal death but only calpain is necessary for death. J Neurochem 2002;82:1208-1220.
42. Momeni HR, Kanje M. The calpain inhibitor VI prevents apoptosis of adult motor neurons. Neuroreport 2005;16:1065-1068.
43. Moore JD, Rothwell NJ, Gibson RM. Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus-dependent. Br J Pharmacol 2002;135:1069-1077.
44. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC. Increased m-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: A role in nerve cell death? Neuroscience 1996;73:979-987.
45. Nakamura M, Yamaguchi M, Sakai O, Inoue J. Exploration of cornea permeable calpain inhibitors as anti-cataract agents. Bioorg Med Chem 2003;11:1371-1379.
46. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J. p35nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 1997;94:153-157.
47. 2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3-nitropropionic acid. Neurochem Int 2003;43:89-99.
48. Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 2003;278:14162-14167.
49. Nixon RA. The calpains in aging and aging-related diseases. Ageing Res Rev 2003;2:407-418.
50. Nixon RA, Saito KI, Grynspan F, et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann NY Acad Sci 1994;747:77-91.
51. O'Donovan CN, Tobin D, Cotter TG. Prion protein fragment PrP-(106-126) induces apoptosis via mitochondrial disruption in human neuronal SH-SY5Y cells. J Biol Chem 2001;276:43516-43523.
52. Oh SH, Lee BH, Lim SC. Cadmium induces apoptotic cell death in WI 38 cells via caspase-dependent Bid cleavage and calpain-mediated mitochondrial Bax cleavage by Bcl-2-independent pathway. Biochem Pharmacol 2004;68:1845-1855.
53. O'Hare MJ, Kushwaha N, Zhang Y, et al. Differential roles of nuclear and cytoplasmic cyclin-dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 2005;25:8954-89566.
54. Pang Z, Bondada V, Sengoku T, Siman R, Geddes JW. Calpain facilitates the neuron death induced by 3-nitropropionic acid and contributes to the necrotic morphology. J Neuropathol Exp Neurol 2003;62:633-643.
55. Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non-erythroid alpha II-spectrin and calpain-cleaved alpha II-spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 2001;78:1297-1306.
56. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 2005;280:6447-6454.
57. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 2004;14:215-222.
58. Rami A, Agarwal R, Botez G, Winckler J. μ-Calpain activation, DNA fragmentation, and synergistic effects of caspase and calpain inhibitors in protecting hippocampal neurons from ischemic damage. Brain Res 2000;866:299-312.
59. Saatman KE, Murai H, Bartus RT, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci USA 1996;93:3428-3433.
60. Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 1993;90:2628-2632.
61. Saulle E, Gubellini P, Picconi B, et al. Neuronal vulnerability following inhibition of mitochondrial complex II: A possible ionic mechanism for Huntington's disease. Mol Cell Neurosci 2004;25:9-20.
62. Sedarous M, Keramaris E, O'Hare M, et al. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 2003;278:26031-26038.
63. Sen A, Thom M, Martinian L, Jacobs T, Nikolic M, Sisodiya SM. Deregulation of cdk5 in hippocampal sclerosis. J Neuropathol Exp Neurol 2006;65:55-66.
64. Sharma AK, Rohrer B. Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J Biol Chem 2004;279:35564-35572.
65. Selvakumar P, Smith-Windsor E, Bonham K, Sharma RK. N- Myristoyltransferase 2 expression in human colon cancer: Cross-talk between the calpain and caspase system. FEBS Lett 2006;580:2021-2026.
66. Siman R, Gall C, Perlmutter LS, Christian C, Baudry M, Lynch G. Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain. Brain Res 1985;347:399-403.
67. Smith PD, Crocker SJ, Jackson-Lewis V, et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100:13650-13655.
68. Smith PD, Mount MP, Shree R, et al. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 2006;26: 440-447.
69. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002;33:1194-1199.
70. Strachan GD, Koike MA, Siman R, Hall DJ, Jordan-Sciutto KL. E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. J Cell Biochem 2005;96:728-740.
71. Takano J, Tomioka M, Tsubuki S, et al. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem 2005;280:16175-16184.
72. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease? Biochim Biophys Acta 2004; 1697:137-142.
73. 2+ influx and not via calpain inhibition. Neuropharmacology 2002;42:706-713.
74. Veeranna Kaji T, Boland B, Odrljin T, et al. Calpain mediates calcium-induced activation of the erk1, 2 MAPK pathway and cytoskeletal phosphorylation in neurons: Relevance to Alzheimer's disease. Am J Pathol 2004;165:795-805.
75. Wang KK, Nath R, Posner A, et al. An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA 1996;93:6687-6692.
76. Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD. Calpain inhibition protects against taxol-induced sensory neuropathy. Brain 2004;127:671-679.
77. Warren MW, Kobeissy FH, Liu MC, Hayes RL, Gold MS, Wang KK. Concurrent calpain and caspase-3 mediated proteolysis of alpha II-spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury. Life Sci 2005;78:301-309.
78. Wood DE, Newcomb EW. Caspase-dependent activation of calpain during drug-induced apoptosis. Biol Chem 1999;274:8309-8315.
79. Wood DE, Thomas A, Devi LA, et al. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 1998;17:1069-1078.
80. Yadavalli R, Guttmann RP, Seward T, Centers AP, Williamson RA, Telling GC. Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation. J Biol Chem 2004;279:21948-21956.
81. Yamashima T. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog Neurobiol 2000;62:273-295.
82. Yang L, Sugama S, Mischak RP, et al. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis 2004;17:250-259.
83. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005;352:2413-2423.
84. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. Cyclin-dependent kinase inhibitors attenuate protein hyperphosphorylation, cytoskeletal lesion formation, and motor defects in Niemann-Pick Type C mice. Am J Pathol 2004;165:843-853.
85. Zheng YL, Kesavapany S, Gravell M, et al. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 2005;24:209-220.